NIH Offers Eos Detection Antibody for Licensing
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The notice makes a government-owned NIH invention available for commercial licensing: a monoclonal antibody called 18H2 that can detect the Eos protein in regulatory T cells. This mainly matters to biotech companies, research-tool makers, immunology labs, and drug developers working on autoimmune disease or immune regulation. Interested companies can contact NIAID’s technology transfer office, and they may need to sign a confidentiality agreement to review unpublished details.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- NIH is offering monoclonal antibody 18H2 for commercial licensing.
- The antibody is designed to detect Eos in both human and mouse regulatory T cells.
- Interested parties must contact NIAID and may need a confidentiality agreement to access unpublished technical details.
Obligations
What this law requires
Companies or researchers seeking copies of unpublished information about NIH/NIAID monoclonal antibody 18H2 must sign a Confidential Disclosure Agreement before receiving those materials.
Entities interested in licensing the government-owned NIH/NIAID monoclonal antibody 18H2 should contact NIAID’s Technology Transfer and Intellectual Property Office or the named NIH licensing contact to obtain licensing information.